Xencor reports phase 1 data for cancer drug XmAb819
AI Summary
Xencor reported Phase 1 data for XmAb819, an investigational cancer drug. The brief contains no details on results or safety findings.
Related Articles
Kano proposes N332bn for education in 2027
Punch Nigeria —
Senate probes telecom firms over failed calls, airtime deductions
Punch Nigeria —
Tinubu rewards victorious Flamingos with N100m bonds each
Punch Nigeria —
COP31: UN chief demands $1.3tn finance for developing countries
Punch Nigeria —
Edo gov promises traders free shop allocation at renovated market
Punch Nigeria —
Lowe’s stock may move 4.7% on Nov. 18 earnings report
Investing.com —